Online citations, reference lists, and bibliographies.

Pomalidomide Alone Or In Combination With Low-dose Dexamethasone In Relapsed And Refractory Multiple Myeloma: A Randomized Phase 2 Study.

Paul G Richardson, David S Siegel, Ravi Vij, Craig C. Hofmeister, Rachid Baz, Sundar Jagannath, Christine Chen, Sagar Lonial, Andrzej J Jakubowiak, Nizar Jacques Bahlis, Kevin W. Song, Andrew J. Belch, Noopur Raje, Chaim Shustik, Suzanne Lentzsch, Martha Lacy, Joseph Mikhael, Jeffrey V. Matous, David H Vesole, Min Chen, Mohamed Zaki, Christian Jacques, Zhinuan Yu, Kenneth C. Anderson
Published 2014 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
This multicenter, open-label, randomized phase 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (LoDEX) in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior therapies (including lenalidomide [LEN] and bortezomib [BORT]) and had progressed within 60 days of their last therapy were randomized to POM (4 mg/day on days 1-21 of each 28-day cycle) with/without LoDEX (40 mg/week). The primary end point was progression-free survival (PFS). In total, 221 patients (median 5 prior therapies, range 1-13) received POM+LoDEX (n = 113) or POM (n = 108). With a median follow-up of 14.2 months, median PFS was 4.2 and 2.7 months (hazard ratio = 0.68, P = .003), overall response rates (ORRs) were 33% and 18% (P = .013), median response duration was 8.3 and 10.7 months, and median overall survival (OS) was 16.5 and 13.6 months, respectively. Refractoriness to LEN, or resistance to both LEN and BORT, did not affect outcomes with POM+LoDEX (median PFS 3.8 months for both; ORRs 30% and 31%; and median OS 16 and 13.4 months). Grade 3-4 neutropenia occurred in 41% (POM+LoDEX) and 48% (POM); no grade 3-4 peripheral neuropathy was reported. POM+LoDEX was effective and generally well tolerated and provides an important new treatment option for RRMM patients who have received multiple prior therapies. This trial was registered at www.clinicaltrials.gov as #NCT00833833.
This paper references
Prevention of thalidomideand lenalidomideassociated thrombosis in myeloma
A Palumbo (2008)
10.1200/JCO.2004.10.052
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Steve A. Schey (2004)
Overcoming resistance; the use of pomalidomide (POM) and dexamethasone (DEX) in re-sensitizing lenalidomide (LEN)-resistant multiple myeloma (MM) cells
E Rychack (2011)
10.1200/JCO.2009.23.6802
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Martha Q Lacy (2009)
10.4065/79.7.867
Clinical course of patients with relapsed multiple myeloma.
Shaji K Kumar (2004)
A phase 2 study of single-agent carfilzomib (PX-171-003A1) in patients with relapsed and refractory multiple myeloma
DS Siegel (2012)
10.1056/NEJMOA070594
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Meletios Athanasios Dimopoulos (2007)
10.1182/blood-2009-02-200543
Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.
Yi-bing Xu (2009)
10.1182/BLOOD.V120.21.727.727
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Paul G Richardson (2012)
10.1038/sj.leu.2405062
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Antonio Palumbo (2008)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Laura G. Corral (1999)
10.1158/1078-0432.CCR-10-1805
Treatment Options for Relapsed and Refractory Multiple Myeloma
Sagar Lonial (2011)
10.1111/j.1600-0609.2008.01121.x
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
Marie von Lilienfeld-Toal (2008)
10.1056/NEJMoa030288
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G Richardson (2003)
10.1182/blood.V96.9.2943
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima (2000)
10.1182/blood-2012-09-452375
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Xavier Leleu (2013)
10.1038/leu.2009.236
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Hang Quach (2010)
10.1182/blood-2010-10-300970
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Nikhil C. Munshi (2011)
10.1182/BLOOD.V120.21.2979.2979
A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
James R. Berenson (2012)
10.1182/blood-2011-04-348896
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Martha Q Lacy (2011)
10.1634/theoncologist.12-6-664
New drugs for myeloma.
Paul G Richardson (2007)
10.1158/0008-5472.CAN-08-4898
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Laure Escoubet-Lozach (2009)
10.1038/leu.2011.196
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji K Kumar (2012)
Pomalidomide ( CC 4047 ) plus low dose dexamethasone ( Pom / dex ) is active and well tolerated in lenalidomide refractory multiple myeloma ( MM )
MQ Lacy (2010)
10.1046/j.1365-2141.1998.00930.x
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Joan Bladé (1998)
10.1182/BLOOD.V120.21.74.74
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
Jatin J. Shah (2012)
10.1182/blood.V99.12.4525
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Nicholas Mitsiades (2002)
Prevention of thalidomide- and lenalidomideassociated thrombosis in myeloma. Leukemia
A Palumbo (2008)
10.1182/BLOOD.V120.21.446.446
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma
Antonio Palumbo (2012)
10.1038/leu.2010.190
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Martha Q Lacy (2010)
10.1182/blood-2004-03-0828
Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis.
Ki-Ryang Koh (2005)
10.1182/BLOOD.V120.21.4062.4062
Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort
Rachid Baz (2012)
10.1182/blood-2005-08-3450
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
Gülsüm Anderson (2006)
10.1200/JCO.2010.32.8435
Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications.
Avet-Loiseau Hervé (2011)
Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
M Dimopoulos (2007)
International Myeloma Working Group. Prevention of thalidomide-and lenalidomideassociated thrombosis in myeloma
A Palumbo (2008)
10.1200/JCO.2009.23.1811
Phase II trials in journal of clinical oncology.
Stephen A. Cannistra (2009)
10.1038/LEU.2012.15
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji K Kumar (2012)
10.1056/NEJMOA070596
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Donna M. Weber (2007)
10.1182/blood-2012-08-450742
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Paul G Richardson (2013)
10.1182/blood-2012-05-425934
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
David S Siegel (2012)
10.1111/j.1365-2141.2008.07013.x
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Matthew J Streetly (2008)
Pomalidomide and lenalidomide induce
L Escoubet-Lozach
International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma
NC Munshi (2011)
A phase 1/2 study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma
JR Berenson (2012)
10.1200/JCO.2011.36.5726
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Hervé Avet-Loiseau (2012)
10.1016/S1470-2045(13)70380-2
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Jesús F. San Miguel (2013)
10.1038/leu.2009.179
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
Jacob P Laubach (2009)



This paper is referenced by
10.2147/CMAR.S166640
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
Xian-wu Luo (2018)
10.1038/onc.2017.172
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance
Yan Song (2017)
10.3324/haematol.2016.142737
Innovations in treatment and response evaluation in multiple myeloma
Ruth Wester (2016)
10.1080/17474086.2016.1194750
A review of the venous thrombotic issues associated with multiple myeloma
Despina Fotiou (2016)
10.1007/s12185-018-2468-5
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
Shira Naomi Dinner (2018)
10.2146/ajhp160554
The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma
Jill M. Comeau (2018)
10.1007/978-3-319-57901-6_16
Neurological Complications of Targeted Therapies
Deborah A. Forst (2018)
10.1080/14740338.2020.1733968
The safety of current and emerging therapies for multiple myeloma.
Omar Nadeem (2020)
10.1038/leu.2014.248
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma
Saad Zafar Usmani (2014)
10.1016/j.beha.2020.101140
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Benjamin T. Diamond (2020)
10.1016/j.mayocp.2015.11.007
Multiple Myeloma: Diagnosis and Treatment.
S. Vincent Rajkumar (2016)
10.1016/j.clinthera.2017.08.010
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Christopher G Pelligra (2017)
10.2217/fon-2017-0616
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Paul G Richardson (2018)
10.1080/14737140.2019.1685879
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
Evangelos Eleutherakis-Papaiakovou (2019)
10.1182/blood-2017-03-726703
How I treat first relapse of myeloma.
Jean Luc Harousseau (2017)
10.1080/14656566.2017.1340942
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Klaus Podar (2017)
Multiple Myeloma and Other Plasma Cell Dyscrasias
Sundar Jagannath (2016)
10.7150/jca.17999
Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis
Runzhe Chen (2017)
10.1182/blood-2013-03-488676
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Alessandra Larocca (2013)
10.12788/jcso.0376
New myeloma drugs improve response and extend survival
Kenneth Anderson (2017)
10.5507/bp.2018.064
Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.
Jiri Minarik (2018)
10.1200/JCO.2014.55.5748
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Constantine S. Mitsiades (2015)
10.1002/ajh.24402
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
Sundararajan Vincent Rajkumar (2016)
10.1093/annonc/mdv325
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
Meletios Athanasios Dimopoulos (2015)
10.3390/cancers12010191
Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools
Despina Fotiou (2020)
10.1038/leu.2014.60
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos (2014)
10.1586/17474086.2014.882764
Current strategies for treatment of relapsed/refractory multiple myeloma
Jacob P Laubach (2014)
10.1517/14740338.2016.1154039
The safety of pomalidomide for the treatment of multiple myeloma
John Rhys Jones (2016)
10.1080/10428194.2016.1177181
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
David S Siegel (2016)
10.1002/hon.2192
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Zhixin Sheng (2016)
10.1177/1078155219889676
Pomalidomide desensitization for hypersensitivity: A case report
Jiyeon J Park (2019)
10.1016/j.soncn.2017.05.005
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
Kimberly Noonan (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar